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Abstract
Background:  Epidemiological studies have revealed a relationship between early growth
restriction and the subsequent development of insulin resistance and type 2 diabetes. Ligation of
the uterine arteries in rats mimics uteroplacental insufficiency and serves as a model of intrauterine
growth restriction (IUGR) and subsequent developmental programming of impaired glucose
tolerance, hyperinsulinemia and adiposity in the offspring. The objective of this study was to
investigate the effects of uterine artery ligation on the skeletal muscle expression of insulin
receptor and key enzymes of LCFA metabolism.
Methods: Bilateral uterine artery ligation was performed on day 19 of gestation in Sprague-Dawley
pregnant rats. Muscle of the posterior limb was dissected at birth and processed by real-time RT-
PCR to analyze the expression of insulin receptor, ACCα, ACCβ (acetyl-CoA carboxylase alpha
and beta subunits), ACS (acyl-CoA synthase), AMPK (AMP-activated protein kinase, alpha2
catalytic subunit), CPT1B (carnitine palmitoyltransferase-1 beta subunit), MCD (malonyl-CoA
decarboxylase) in 14 sham and 8 IUGR pups.
Muscle tissue was treated with lysis buffer and Western immunoblotting was performed to assay
the protein content of insulin receptor and ACC.
Results:  A significant down regulation of insulin receptor protein (p < 0.05) and reduced
expression of ACS and ACCα mRNA (p < 0.05) were observed in skeletal muscle of IUGR
newborns. Immunoblotting showed no significant change in ACCα content.
Conclusion:  Our data suggest that uteroplacental insufficiency may affect skeletal muscle
metabolism down regulating insulin receptor and reducing the expression of key enzymes involved
in LCFA formation and oxidation.
Background
Uteroplacental insufficiency resulting in fetal growth
retardation is a common complication of pregnancy and
a significant cause of perinatal morbidity and mortality.
Epidemiologic studies in humans have shown that
impaired intrauterine growth is associated with an
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increased incidence of insulin resistance, type 2 diabetes,
and cardiovascular disease in the adult [1-6]. These obser-
vations have led to the hypothesis that metabolic and car-
diovascular disease in adulthood arises in utero, in part, as
a result of changes in the development of key endocrine
and metabolic pathways during suboptimal intrauterine
conditions associated with impaired fetal growth. This
hypothesis has been tested experimentally in a number of
species, using a range of techniques to impair fetal growth.
Inducing intrauterine growth retardation (IUGR) by pla-
cental insufficiency or by undernutrition, stress, or hor-
mone treatment of the mother leads to endocrine and
metabolic alterations in the adult offspring in several spe-
cies [7]. However, the mechanisms by which an abnormal
uterine milieu leads to the development of diabetes in
adulthood are not known. To investigate potential seque-
lae of IUGR and the underlying mechanisms, ligation of
the uterine arteries in rats has been used as an animal
model of uteroplacental insufficiency leading to growth
retarded fetuses with a metabolic profile very similar to
that of IUGR human fetuses [8,9]. We have recently
shown that uteroplacental insufficiency, obtained by uter-
ine artery ligation, which leads to IUGR pups, affects the
expression of specific hypothalamic lipid sensing genes
such as the CPT1 isoform C, and acetyl-CoA carboxylase
(ACC) isoforms alpha and beta [10].
Insulin resistance and type 2 diabetes are characterized by
hyperglycemia with hyperinsulinemia, a reduced ability
to oxidize fat, and an accumulation of fat within skeletal
muscle [11,12]. This increase in muscle fat content is
highly associated with insulin resistance [13,14].
Recently, perturbed skeletal muscle insulin signaling has
been reported in adult growth restricted rats [15].
In this study we focused on the hypothesis that uteropla-
cental insufficiency may affect skeletal muscle metabolic
pathways altering the expression of insulin receptor and
of key enzymes of intramuscular lipid metabolism.
Methods
Animal model
Time-dated Sprague-Dawley pregnant rats (Harlan
Sprague Dawley, Inc.) were individually housed under
standard conditions and allowed free access to standard
chow and water. On day 19 of gestation (term is 22 days)
the maternal rats were anesthetized with intramuscular
injections of xylazine (8 mg/Kg) and ketamime (40 mg/
kg) (Sigma-Aldrich, St. Louis, MO), and the abdomen was
opened along the midline. Suture was placed around both
uterine arteries, then either tied or withdrawn before clos-
ing the abdomen [8,9]. Dams recovered quickly from
uterine artery ligation (n = 4) and sham procedures (n =
4), and resumed feeding the same day. After recovery, rats
had ad libitum access to food and water. The pregnant rats
were allowed to deliver spontaneously and at birth pups
were weighted and killed by cervical dislocation. Posterior
limb skeletal muscle tissue was immediately harvested
and frozen in liquid nitrogen and stored at -80°C. 14
sham and 8 IUGR rats from different litters were tested. All
procedures complied with Italian regulations for labora-
tory animal care, according to the guidelines and under
supervision of the Animal Technology Station, Interde-
partmental Service Center, Tor Vergata University, Rome,
Italy.
Plasma assays
At birth, 14 SHAM and 8 IUGR pups were decapitated,
blood was collected and centrifuged at 1900 × g at 4°C for
10 min, and plasma was stored at -80°C. Glucose and
insulin concentrations were measured.
Glucose was determined using a colorimetric commercial
kit (SigmaChemical Co.). Plasma insulin concentrations
were measured in duplicate by a rat/mouse insulin ELISA
kit, using rat insulin as the standard (Linco Research, St.
Charles, MO) according to the manufacturer's instruc-
tions. The intraassay CV was 1.2–8.4%, the interassay CV
was 6.0–17.9%, and the sensitivity limit was 0.2 ng/mL.
RNA isolation and cDNA synthesis
Total RNA was extracted using TriPure (Roche Applied Sci-
ence) according to the manufacturer's instructions and
quantified in duplicate using ultraviolet absorbance at
260 nm. Gel electrophoresis confirmed the integrity of the
samples. 1 μg RNA, pretreated with RNase free DNase
(Invitrogen Co.) was transcribed into the complementary
DNA using the High-Capacity cDNA Archive Kit (Applied
Biosystems) in a final volume of 50 μl following the man-
ufacturer's protocol. To minimize variation in the reverse
transcription reaction, all RNA samples from a single
experimental setup were reverse transcribed simultane-
ously.
Real-time RT-PCR
We explored the expression of key enzymes that regulate
fatty acid metabolism in the muscle. Real-time RT-PCR
was performed on an ABI PRISM 7300 Sequencer Detector
(Applied Biosystems). PCR primers and TaqMan probes
to amplify and detect ACCα, ACCβ, ACS, AMPK, CPT1B,
MCD, Insulin receptor and the housekeeping gene 18S
were commercially available as inventoried assay (Assay-
on-demand Gene Expression Product; Applied Biosys-
tems).
Prior to performing real-time PCR, primer and probe con-
centrations were determined to demonstrate their specifi-
city and optimal reaction condition. 18S was used as an
internal control for differences in cDNA loading. Before
the use of 18S as a control, parallel serial dilution of cDNACardiovascular Diabetology 2008, 7:14 http://www.cardiab.com/content/7/1/14
Page 3 of 7
(page number not for citation purposes)
were quantified to prove the validity of using 18S as an
internal control.
The real-time RT-PCR amplification was performed in
skeletal muscle tissues from fourteen SHAM and eight
IUGR rats. Experiments were performed in triplicate using
96-well tray and optical adhesive covers (Applied Biosys-
tems) in a final reaction mixture of 20 μl containing 3 μl
of undiluted cDNA. Real-time PCR was performed using
Platinum Quantitative PCR SuperMix-UDG with ROX
(Invitrogen Co.). The cycling consisted of 2 min at 50°C,
2 min at 95°C followed by 40 cycles of 95°C for 15 sec
and 60°C for 45 sec. Determination of reaction efficiency
was routinely used as an internal quality control for ade-
quate assay performance. Crossing of threshold (Ct) val-
ues obtained for the target gene were normalized against
each individual 18S value which was run in the same well
of the real time RT-PCR run. Relative quantification of
PCR products was performed using Relative Quantifica-
tion Study software (Applied Biosystems). Results are
expressed in raw relative quantification (RQ) ± standard
errorrs.
Western immunoblotting
Tissues were homogenized in ice with lysis buffer (50 mM
Hepes pH 7.4, 150 mM NaCl, 10 mM NaF, 1 mM Na3VO4,
10% glycerol, 0.5% Triton ×-100, 5 mM EDTA, 10 μl/ml
cocktail protease inhibitors). Lysates were clarified by cen-
trifugation at 13,000 g (30 minutes, 4°C), and protein
concentration in the supernatant were determined by the
Bradford assay (Bio-Rad Laboratories, CA, USA) using
bovine serum albumin as a standard. Eighty micrograms
of the extracted proteins were separated by SDS-PAGE on
3–8% Tricine gel (Bio-Rad Laboratories, CA, USA) and
blotted onto ECL nitrocellulose membrane (Amersham
Biosciences UK, Ltd., Little Chalfont, Buckinghamshire,
UK). The filter was blocked with 5% non-fat dry milk in
TBS-0.1% Tween 20 and then incubated with ACC rabbit
polyclonal antibody (Cell Signaling Technology Inc. Dan-
vers, MA) and insulin-Rβ rabbit polyclonal antibody
(Santa Cruz). After several washes in PBS-0.1% Tween 20,
horseradish peroxidase-conjugated secondary antibody
(1:5,000) (Amersham) was added for 1 hour at RT. The
labelled bands were detected using Amersham ECL west-
ern blotting system according to manufacturer's specifica-
tions. After protein detection, membranes were stripped
with Restore Western Blot Stripping Buffer (Pierce, Rock-
ford IL) and re-blotted with rabbit HRP-conjugated actin
antibody (1:1000) (Santa Cruz). Densitometry analysis of
bands was performed using a Image Quant 5 software
(Molecular Dynamics).
Statistical analysis
Statistical analysis was performed using Sigma Plot for
Windows Version 13.0 (SPSS, Inc, Chicago, IL, USA). Dif-
ferences in gene expression between sham and IUGR rats
were analyzed with one-way ANOVA. Differences
between means from plasma assays and densitometric
analyses were assessed by unpaired two-tailed t test. Dif-
ferences were considered statistically significant at p  <
0.05.
Results
Animal weights and metabolic profile
Birth weights of IUGR animals were significantly lower
than those of controls (SHAM) (mean weight ± SD: 4.0 ±
0.57 versus 6.5 ± 0.32 g, p < 0.001). No significant differ-
ences were observed in blood glucose (63.9 ± 13 vs 62.9 ±
21.5 mg/dL) and insulin (0.34 ± 0.15 vs 0.36 ± 0.16 ng/
mL) levels.
Insulin Receptor
Although a tendency toward a decrease of insulin receptor
mRNA expression was noted (20% less), these changes
did not achieve statistical significance (Figure 1).
Immunoblot analysis indicated a significant down regula-
tion of insulin receptor in skeletal muscle of IUGR ani-
mals when compared with SHAM (control) (p < 0.05,
Figure 2).
Expression of LCFA metabolism regulatory enzymes
LCFAs act as nutrient abundance signals in the muscle.
The expression of key enzymes that regulate muscle LCFA
metabolism was assessed. The expression of ACCα and
ACS mRNA levels was significantly reduced (by 54% and
66% respectively, p < 0.05) in skeletal muscle of IUGR rats
at birth (Figure 3), whereas no significant differences in
Insulin receptor mRNA expression in skeletal muscle of  SHAM (n = 14) and IUGR rats (n = 8) Figure 1
Insulin receptor mRNA expression in skeletal muscle 
of SHAM (n = 14) and IUGR rats (n = 8). Transcripts 
were measured by real-time RT-PCR using appropriate prim-
ers and normalized to 18S mRNA. Data are expressed as rel-
ative quantification vs. SHAM group (RQ = 1). Bars represent 
standard errors.Cardiovascular Diabetology 2008, 7:14 http://www.cardiab.com/content/7/1/14
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the expression of ACCβ, AMPK, and MCD were observed.
Expression of muscle specific CPT1B  was measured by
quantitative RT-PCR but no significant difference between
IUGR and SHAM pups was found.
ACCα immunoblotting analysis showed no differences
between IUGR and SHAM animals thus suggesting a post-
transcriptional regulation (Figure 4). ACS immunoblot-
ting analysis couldn't be performed for unavailability of
the specific antibodies.
Discussion
Uteroplacental insufficiency limits availability of sub-
strates to the fetus and retards growth during gestation,
ultimately leading to IUGR. Alterations in the intrauterine
milieu have a profound impact on glucose homeostasis in
the offspring, culminating in the development of insulin
resistance, glucose intolerance and type 2 diabetes in
adulthood.
The etiology of insulin resistance within skeletal muscle in
the human with type 2 diabetes is multifactorial, involv-
ing impairments in hormonal signaling, enzyme and
transporter activity, and substrate availability. Previous
studies also implicated decreased oxidative capacities of
skeletal muscle of human diabetics as contributory to
insulin resistance [16].
To investigate the effects of uteroplacental insufficiency
on the expression of insulin receptor in muscle, we stud-
ied an animal model of intrauterine growth retardation
obtained by bilateral uterine artery ligation. In this model,
the resulting uteroplacental insufficiency leads to growth
retarded fetuses with a metabolic profile very similar to
that of IUGR human fetuses [8,9]. These animals exhibit
impaired oxidative phosphorylation in skeletal muscle
[17], mild peripheral insulin resistance and β-cell secre-
tory defects very early in life but have adequate compen-
satory insulin secretion for several weeks [18]. However,
eventually, β-cell compensation fails, and overt diabetes
occurs at age 3–6 months [9]. More recently, it has been
described in the same animal model that ligated offspring
showed impaired glucose tolerance from the age of 15
weeks as well as elevated glycosylated hemoglobin and
corticosterone levels [19].
Our data show for the first time reduced protein levels of
insulin receptor in skeletal muscle of IUGR animals. The
lack of statistical significance in insulin receptor mRNA
expression is probably due to the relative low number of
examined samples. Most of previous studies focused on
downstream effectors of insulin actions in peripheral tis-
sues without determining insulin receptor expression. In
rat model, Ozanne et al. [20] showed that maternal pro-
tein restriction leads to muscle insulin resistance. Soleus
muscle from growth restricted offspring had similar basal
glucose uptakes compared with the control group, but
whilst insulin stimulated glucose uptake into control
muscle, it had no effect on growth restricted offspring
Expression of acetyl-CoA carboxylase isoenzyme alpha  (ACCα) and beta (ACC β), acyl-CoA synthase (ACS), AMP- activated protein kinase (AMPK), carnitine palmitoyltrans- ferase-1 isoenzyme B (CPT1B), malonyl-CoA decarboxylase  (MCD), in IUGR rat skeletal muscle Figure 3
Expression of acetyl-CoA carboxylase isoenzyme 
alpha (ACCα) and beta (ACC β), acyl-CoA synthase 
(ACS), AMP-activated protein kinase (AMPK), carni-
tine palmitoyltransferase-1 isoenzyme B (CPT1B), 
malonyl-CoA decarboxylase (MCD), in IUGR rat 
skeletal muscle. Transcripts were measured by real-time 
RT-PCR using appropriate primers and normalized to 18S 
mRNA. Data are expressed as relative quantification vs. 
SHAM group (RQ = 1). Bars represent standard errors. *P < 
0.05.
Insulin receptor beta subunit protein expression in skeletal  muscle of SHAM (n = 14) and IUGR rats (n = 8) on day 0 Figure 2
Insulin receptor beta subunit protein expression in 
skeletal muscle of SHAM (n = 14) and IUGR rats (n = 
8) on day 0. A, Western immunoblotting analysis; B, densit-
ometric analysis.*P < 0.05.Cardiovascular Diabetology 2008, 7:14 http://www.cardiab.com/content/7/1/14
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muscle. This impaired insulin action was not related to
changes in expression of either the insulin receptor or glu-
cose transporter 4 (GLUT4). However, growth restricted
offspring muscle expressed significantly less of the zeta
isoform of protein kinase C (PKC ζ) compared with con-
trols. This PKC isoform has been shown to be positively
involved in GLUT4-mediated glucose transport. We have
used a different model of intrauterine growth restriction
based upon uterine artery ligation in which blood flow to
the fetus is not ablated but reduced to a similar degree to
that observed in human pregnancies complicated by uter-
oplacental insufficiency. Furthermore, whilst Ozanne et
al. [20] studied 15-month-old animals, we investigated
rats at birth. The use of only hind limb skeletal muscle
might represent a limiting factor since an important dif-
ference between type 1 (slow) and type 2 (fast) fibers
could exist. However, at birth it is practically impossible
to select muscle fibers.
In humans, Jaquet et al. [21] demonstrated that insulin
resistance is associated with an impaired regulation of
GLUT4 gene expression by insulin in IUGR-born subjects
in both skeletal muscle and adipose tissue.
Impairment of muscle fat metabolism is highly associated
with insulin resistance. Our study shows for the first time
that uteroplacental insufficiency leads to reduced ACS and
ACCα mRNA expression in skeletal muscle at birth. In
intramuscular lipid metabolism, ACS is the key enzyme
for converting free fatty acids into LCFA-CoA. ACC cata-
lyzes the formation of malonyl-CoA, an essential sub-
strate for fatty acid synthesis in lipogenic tissues and a key
regulatory molecule in muscle, brain, and other tissues
[22]. Three CPT1 isoforms with various tissue distribu-
tions and encoded by distinct genes have been identified:
liver (CPT1A) [23], muscle (CPT1B) [24], and brain
(CPT1C) [25] Cellular levels of malonyl-CoA repress
CPT1 activity and decrease LCFA-CoAs oxidation. There-
fore, the final effect of reduced expression of both ACS
and ACCα would be the decrease of intramuscular LCFAs.
This finding is consistent with our recent study in hypoth-
alamus of IUGR rats, showing significant decreased ACCα
and ACCβ expression at birth [10]. Taken together these
findings suggest that intrauterine programming may affect
key enzymes of lipid metabolism at multiple levels. In
muscle, however, ACCα protein content was not affected
thus suggesting post-transcriptional regulation.
Lipids are implicated in the development of insulin resist-
ance in skeletal muscle. This seems to be linked to an
imbalance between lipid supply and lipid oxidation, the
latter being related to decreased mitochondrial oxidative
capacity in states of insulin resistance [26]. In humans, it
has been described that during physiological hyperglyc-
emia with hyperinsulinemia and maintained FFA concen-
trations (i.e., a condition that mimics the insulin-resistant
state), human skeletal muscle malonyl-CoA concentra-
tions are significantly increased and are directly associated
with a reduction in LCFA oxidation and functional CPT-1
activity [27].
As LCFA oxidative capacity in mitochondria is low in sub-
jects with insulin resistance [20,28-32], mitochondrial
dysfunction and thereby decreased lipid oxidation has
been considered to play a key role in the development of
insulin resistance. Lane et al. reported an increase in trig-
lyceride levels in IUGR rats [33] Accordingly, a connection
between mitochondrial dysfunction, increased intramus-
cular triacylglycerol levels, and insulin resistance has been
described in insulin-resistant offspring of patients with
type 2 diabetes [34].
LCFAs may influence glucose metabolism by multiple
mechanisms. LCFAs inhibit hexokinase activity [35] thus
reducing glucose metabolism. They are also a substrate for
the synthesis of ceramide which is increased in muscle of
insulin-resistant rats [36]. LCFAs may interfere with insu-
lin signaling by activating protein kinase C. PKC in turn
inhibits insulin signaling by phosphorylation of the ser-
ine residues on the insulin receptor [37,38] and insulin
receptor substrate-1 (IRS-1) [39], thus inhibiting the tyro-
sine phosphorylation of IRS-1. Patients with type 2 diabe-
tes have increased PKC protein levels in the rectus
abdominal muscle [40] and decreased muscle insulin
receptor tyrosine kinase activity, which could be restored
by phosphatase treatment in vitro, possibly suggesting
Acetyl-CoA carboxylase isoenzyme alpha (ACCα) protein  expression in skeletal muscle of SHAM (n = 14) and IUGR  rats (n = 8) on day 0 Figure 4
Acetyl-CoA carboxylase isoenzyme alpha (ACCα) 
protein expression in skeletal muscle of SHAM (n = 
14) and IUGR rats (n = 8) on day 0. A, western immuno-
blotting analysis; B, densitometric analysis.Cardiovascular Diabetology 2008, 7:14 http://www.cardiab.com/content/7/1/14
Page 6 of 7
(page number not for citation purposes)
increased serine phosphorylation of the insulin receptor
due to increased PKC activity [37].
We speculate that intrauterine limited supply of substrates
secondary to uteroplacental insufficiency may lead to
down regulation of insulin receptor in skeletal muscle. We
hypothesize that reduced intramuscular content of LCFAs
secondary to reduced expression of both ACS and ACC
may represent a transient compensatory mechanism to
counteract insulin resistance during early postnatal life.
Conclusion
Uteroplacental insufficiency may affect skeletal muscle
metabolism down regulating insulin receptor and reduc-
ing the expression of key enzymes involved in LCFA for-
mation and oxidation. We speculate that decreased
intramuscular lipid accumulation may represent a tran-
sient compensatory mechanism to counteract insulin
resistance.
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